 Home > Active Ingredient News > Digestive System Information > IBD: Higher concentrations of infliximab can improve blood and fecal neutrophil biomarkers in patients with Crohn's disease

IBD: Higher concentrations of infliximab can improve blood and fecal neutrophil biomarkers in patients with Crohn's disease

 Last Update: 2021-06-29
 Source: Internet
 Author: User

Tags

food drug administration

trichomonas disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Endoscopic evaluation is still the gold standard for monitoring the treatment response of patients with Crohn's disease (CD).
However, frequent endoscopy for assessment of disease severity will increase the economic and physical burden of patients
.
Therefore, there is a growing need for biomarkers to replace invasive detection because it can avoid frequent invasive surgery

Endoscopic evaluation is still the gold standard for monitoring the treatment response of patients with Crohn's disease (CD).

Researchers in the Pediatric Crohn's Disease (CD) cohort study analyzed the differences in FCP, LCT, and nCD64 levels of patients before and after induction of IFX therapy

In 56 CD patients, ROC curve analysis showed that when LCT <8.
06 (area under the receiver's operating characteristics [AUROC], 0.
934, P <0.
001) and nCD64 <6.
12 (AUROC, 0.
76, P = 0.
02) are the ideal first The cut-off value of FCP biomarker remission at 14 weeks
.
The trough concentration of the drug during IFX induction therapy>9.

4 µg/mL (AUROC, 0.

Figure: Higher drug concentration of infliximab can improve blood and fecal neutrophil biomarkers in patients with Crohn's disease

This study determined the cut-off values of neutrophil fecal and blood biomarkers for the biochemical remission after IFX induction therapy and the trough concentration level of therapeutic drugs, which can provide some help for clinical treatment
.

Original source:

Ruben J Colman.

Et al.

Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

GLYEROL USP

CAS No.: 56-81-5

Pharmacy Grade

$1.04-1.09/KG EXW

SEMAGLUTIDE GMP grade

CAS No.: 910463-68-2

Pharmacy Grade

$270.00/G FOB

Berberine2086-83-1

CAS No.: 2086-83-1

$1-1.1/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.